Harrow, INC 10-Q quarterly reports

Harrow Inc. announced its Q2 2026 financial results, showing an increase in total revenues driven by its branded segment, but also reporting a significant net loss and increased operating expenses.

Harrow, Inc. announced significant revenue increases and key strategic acquisitions in its Q3 2025 filing, alongside a major debt refinancing and new credit facility.

Harrow, Inc. reported significant revenue growth in its branded ophthalmology segment for the first half of 2025, alongside improved cash flow from operations, but faces substantial debt maturities in early 2026.

Harrow Inc. saw a revenue increase in Q1 2025, driven by strong sales of branded ophthalmology products, while navigating debt refinancing and regulatory considerations.

Harrow Inc. experienced a significant increase in product sales during the third quarter of 2024, but still reported a net loss due to increased operating expenses and interest costs.

Harrow Inc. saw a significant increase in product sales but reported a net loss for the second quarter of 2024, according to its latest financial report.

Harrow Inc. saw a significant increase in revenue during the first quarter of 2024, primarily driven by growth in its branded ophthalmology product sales.